PDF(Pubmed)
Abstract：
BACKGROUND: Radiomics can provide quantitative features from medical imaging that can be correlated with various biological features and diverse clinical endpoints. Delta radiomics, on the other hand, consists in the analysis of feature variation at different acquisition time points, usually before and after therapy. The aim of this study was to provide a systematic review of the different delta radiomics approaches.
METHODS: Eligible articles were searched in Embase, Pubmed, and ScienceDirect using a search string that included free text and/or Medical Subject Headings (MeSH) with 3 key search terms: \'radiomics,\' \'texture,\' and \'delta.\' Studies were analyzed using QUADAS-2 and the RQS tool.
RESULTS: Forty-eight studies were finally included. The studies were divided into preclinical/methodological (5 studies, 10.4%); rectal cancer (6 studies, 12.5%); lung cancer (12 studies, 25%); sarcoma (5 studies, 10.4%); prostate cancer (3 studies, 6.3%), head and neck cancer (6 studies, 12.5%); gastrointestinal malignancies excluding rectum (7 studies, 14.6%) and other disease sites (4 studies, 8.3%). The median RQS of all studies was 25% (mean 21% ± 12%), with 13 studies (30.2%) achieving a quality score < 10% and 22 studies (51.2%) < 25%.
CONCLUSIONS: Delta radiomics shows potential benefit for several clinical endpoints in oncology, such asdifferential diagnosis, prognosis and prediction of treatment response, evaluation of side effects. Nevertheless, the studies included in this systematic review suffer from the bias of overall low methodological rigor, so that the conclusions are currently heterogeneous, not robust and hardly replicable. Further research with prospective and multicenter studies is needed for the clinical validation of delta radiomics approaches.
METHODS: Eligible articles were searched in Embase, Pubmed, and ScienceDirect using a search string that included free text and/or Medical Subject Headings (MeSH) with 3 key search terms: \'radiomics,\' \'texture,\' and \'delta.\' Studies were analyzed using QUADAS-2 and the RQS tool.
RESULTS: Forty-eight studies were finally included. The studies were divided into preclinical/methodological (5 studies, 10.4%); rectal cancer (6 studies, 12.5%); lung cancer (12 studies, 25%); sarcoma (5 studies, 10.4%); prostate cancer (3 studies, 6.3%), head and neck cancer (6 studies, 12.5%); gastrointestinal malignancies excluding rectum (7 studies, 14.6%) and other disease sites (4 studies, 8.3%). The median RQS of all studies was 25% (mean 21% ± 12%), with 13 studies (30.2%) achieving a quality score < 10% and 22 studies (51.2%) < 25%.
CONCLUSIONS: Delta radiomics shows potential benefit for several clinical endpoints in oncology, such asdifferential diagnosis, prognosis and prediction of treatment response, evaluation of side effects. Nevertheless, the studies included in this systematic review suffer from the bias of overall low methodological rigor, so that the conclusions are currently heterogeneous, not robust and hardly replicable. Further research with prospective and multicenter studies is needed for the clinical validation of delta radiomics approaches.
摘要：
背景：影像组学可以提供来自医学成像的定量特征，这些特征可以与各种生物学特征和各种临床终点相关。Delta影像组学,另一方面,包括在不同采集时间点的特征变化分析，通常在治疗之前和之后。本研究的目的是对不同的delta放射组学方法进行系统评价。
方法：在Embase中搜索了符合条件的文章，Pubmed,和ScienceDirect使用包含自由文本和/或医学主题词（MeSH）的搜索字符串以及3个关键搜索词：\'\'纹理,\'和\'delta。使用QUADAS-2和RQS工具分析研究。
结果：48项研究最终被纳入。这些研究分为临床前/方法学(5项研究，10.4%)；直肠癌(6项研究，12.5%)；肺癌(12项研究，25%)；肉瘤(5项研究，10.4%)；前列腺癌(3项研究，6.3%），头颈癌（6项研究，12.5%)；不包括直肠的胃肠道恶性肿瘤(7项研究，14.6%)和其他疾病部位(4项研究，8.3%）。所有研究的RQS中位数为25%（平均21%±12%），13项研究（30.2%）质量评分<10%，22项研究（51.2%）<25%。
结论：Delta放射组学显示了肿瘤学的几个临床终点的潜在益处，比如鉴别诊断，预后和治疗反应的预测，副作用评估。然而，本系统综述中包含的研究存在总体上方法学严谨程度低的偏见，所以目前的结论是不同的，不健壮，难以复制。对于delta放射组学方法的临床验证，需要进行前瞻性和多中心研究的进一步研究。
方法：在Embase中搜索了符合条件的文章，Pubmed,和ScienceDirect使用包含自由文本和/或医学主题词（MeSH）的搜索字符串以及3个关键搜索词：\'\'纹理,\'和\'delta。使用QUADAS-2和RQS工具分析研究。
结果：48项研究最终被纳入。这些研究分为临床前/方法学(5项研究，10.4%)；直肠癌(6项研究，12.5%)；肺癌(12项研究，25%)；肉瘤(5项研究，10.4%)；前列腺癌(3项研究，6.3%），头颈癌（6项研究，12.5%)；不包括直肠的胃肠道恶性肿瘤(7项研究，14.6%)和其他疾病部位(4项研究，8.3%）。所有研究的RQS中位数为25%（平均21%±12%），13项研究（30.2%）质量评分<10%，22项研究（51.2%）<25%。
结论：Delta放射组学显示了肿瘤学的几个临床终点的潜在益处，比如鉴别诊断，预后和治疗反应的预测，副作用评估。然而，本系统综述中包含的研究存在总体上方法学严谨程度低的偏见，所以目前的结论是不同的，不健壮，难以复制。对于delta放射组学方法的临床验证，需要进行前瞻性和多中心研究的进一步研究。
